[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354628-105":59,"doc-detail-354628-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cellular-immunotherapy-for-cervical-cancer-next-therapeutics-frontiers","Cellular Immunotherapy for Cervical Cancer - Next Therapeutics Frontiers","","Cervical cancer, especially in advanced stages, requires novel therapeutic strategies. Cellular immunotherapy targets constitutively expressed HPV E6/E7 oncoproteins as tumor-specific antigens and evaluates four major platforms: tumor-infiltrating lymphocytes (TILs), TCR-engineered T cells, CAR-T cells, and CAR-NK cells. The review weighs preclinical rationale, clinical trial progress, safety issues, and manufacturing constraints, highlighting durable responses with TILs, HLA limitation for TCR-T, toxicity and tumor microenvironment suppression for CAR-T, and off-the-shelf promise for CAR-NK. Future directions emphasize rational combinations and next-generation engineering to reduce costs and complexity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cellular-immunotherapy-for-cervical-cancer-next-therapeutics-frontiers/354628/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cellular-immunotherapy-for-cervical-cancer-next-therapeutics-frontiers/354628.png","ImageObject",300,407,{"name":92,"@type":93},"OmBimo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is cellular immunotherapy considered promising for cervical cancer?","Question",{"text":113,"@type":114},"It exploits the constitutive expression of HPV E6/E7 oncoproteins as near-ideal tumor-specific antigens, supporting targeted immune recognition.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What distinguishes TILs, TCR-engineered T cells, CAR-T cells, and CAR-NK cells?",{"text":118,"@type":114},"TILs leverage tumor-infiltrating lymphocytes; TCR-T cells target intracellular viral epitopes but are HLA-restricted; CAR-T cells provide MHC-independent recognition but face on-target/off-tumor toxicity and tumor microenvironment suppression; CAR-NK cells offer a favorable safety profile and off-the-shelf potential.",{"name":120,"@type":111,"acceptedAnswer":121},"What challenges must be overcome to expand these therapies to broader settings?",{"text":122,"@type":114},"Key barriers include manufacturing complexity, safety/toxicity concerns, and high costs, motivating future rational combinations and next-generation engineering approaches.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354628,1790162241,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[http://doi.org/10.32604/or.2026.084736](http://doi.org/10.32604/or.2026.084736)  \nREVIEW  \nCellular Immunotherapy for Cervical Cancer: Next Therapeutics Frontiers Danning Zhao and Qin Liu*  \nDepartment of Obstetrics and Gynecology, Gusu School of Nanjing Medical University, the First People’s Hospital ofKunshan, Suzhou, China  \n*Corresponding Author: Qin Liu. Email: [liuqinchina@163.com](liuqinchina@163.com)  \n[Received: 28 April 2026](Received: 28 April 2026); [Accepted: 04 June 2026](Accepted: 04 June 2026); [Published: 13 August 2026](Published: 13 August 2026)  \nABSTRACT: Cervical cancer, particularly its advanced stages, requires novel therapeutic paradigms. Cellular immunotherapy exploits the constitutive expression of HPV E6/E7 oncoproteins as near-ideal tumor-specific antigens. This review systematically evaluates four principal platforms under investigation: tumor-infiltrating lymphocytes (TILs), TCR-engineered T cells, CAR-T cells, and CAR-NK cells. We critically analyze the preclinical rationale, clinical trial landscape, safety considerations, and manufacturing challenges for each modality. TIL therapy has achieved durable complete responses and an FDA Breakthrough Therapy designation. TCR-T cells enable precise targeting of intracellular viral epitopes but are HLA-restricted. CAR-T cells offer potent, MHC-independent recognition, yet face on-target/off-tumor toxicity and a suppressive tumor microenvironment. CAR-NK cells present a favorable safety profile and off-the-shelf potential. We conclude that the future of this field lies in rational combination strategies (e.g., with immune checkpoint blockade) and next-generation engineering (e.g., armored CARs, logic gates, allogeneic platforms) to overcome manufacturing complexity, toxicity, and high costs. Overcoming these barriers is essential to extend these therapies to resource-limited settings where the burden of cervical cancer is highest.  \nKEYWORDS: Cell therapy; cervical cancer; immunotherapy; tumor-infiltrating lymphocytes; T-cell receptor (TCR)-engineered T cells; chimeric antigen receptor (CAR)-T cells; clinical trials  \n1 Introduction  \nCervical cancer persists as a striking example of global oncological inequity and remains the fourth most common malignancy and fourth leading cause of cancer-related mortality among women worldwide [1,2] . According to GLOBOCAN 2022 estimates, the disease accounted for approximately 661,000 incident cases and 348,000 deaths globally, with a profound disparity in outcomes, 94% of these deaths occur in low-and middle-income countries, a trend attributable principally to inadequate access to prophylactic vaccination and high-quality screening infrastructure [3] . China bears a particularly substantial disease burden, with an estimated 150,700 new diagnoses and 55,700 deaths annually [4–6] . Notably, despite incremental improvements in cytology and HPV-based screening coverage, incidence rates in China exhibit a concerning upward trajectory among younger demographic cohorts [7] . The aetiological primacy of persistent infection with high-risk human papillomavirus (HPV) is unequivocal; HPV16 and HPV18 collectively account for over 70% of cervical squamous cell carcinomas globally. Within the general female population in China, the pooled prevalence of high-risk HPV infection approaches 17.70%, indicating a considerable reservoir of premalignant cervical intraepithelial neoplasia and underscoring the exigent need for expanded vaccine dissemination [8–10] . Therapeutic stratification is governed primarily by the International.  \nCopyright © 2026 The Authors. Published by Tech Science Press. This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nFederation of Gynecology and Obstetrics (FIGO) staging system [11] . Early-stage disease (FIGOIA-IB2) is typically managed via radi","cbCaiiWIhOUyUszO","https://ap.wps.com/l/cbCaiiWIhOUyUszO","pdf",3015701,33,"English","# Introduction\n# Therapeutic Paradigms and Platforms\n## Tumor-Infiltrating Lymphocytes (TILs)\n## TCR-Engineered T Cells\n## CAR-T Cells\n## CAR-NK Cells\n# Clinical Evidence, Safety, and Manufacturing Challenges\n# Future Directions and Combination Strategies","[{\"question\":\"Why is cellular immunotherapy considered promising for cervical cancer?\",\"answer\":\"It exploits the constitutive expression of HPV E6/E7 oncoproteins as near-ideal tumor-specific antigens, supporting targeted immune recognition.\"},{\"question\":\"What distinguishes TILs, TCR-engineered T cells, CAR-T cells, and CAR-NK cells?\",\"answer\":\"TILs leverage tumor-infiltrating lymphocytes; TCR-T cells target intracellular viral epitopes but are HLA-restricted; CAR-T cells provide MHC-independent recognition but face on-target/off-tumor toxicity and tumor microenvironment suppression; CAR-NK cells offer a favorable safety profile and off-the-shelf potential.\"},{\"question\":\"What challenges must be overcome to expand these therapies to broader settings?\",\"answer\":\"Key barriers include manufacturing complexity, safety/toxicity concerns, and high costs, motivating future rational combinations and next-generation engineering approaches.\"}]","Cellular Immunotherapy for Cervical Cancer - Next Therapeutics Frontiers | PDF",1790112645,83,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70864a0373670cc88310b0c65f793ec1.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e437504c0642ce0dc412886072e9287.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f04435f7782c877fd3b21eddf39e4ff5.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d27c4e64e849d57c02a0a5457e24d85.webp",980,1268]